Outcome of Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Long-Term Follow-Up in a Single Institution

Allogeneic stem cell transplantation (allo-SCT) has the potential to induce long-term remission in multiple myeloma (MM), but the role of allo-SCT in MM is controversial due to the high rate of treatment-related mortality (TRM). However, although proteasome inhibitors and immunomodulatory drugs have improved the outcome of MM patients, high-risk patients still have a very poor prognosis. This indicates the need for new treatment strategies and identification of patients who might benefit from allo-SCT. We therefore analyzed the outcome of one hundred and forty-seven MM patients who received an allo-SCT at our institution (58 in first line, 89 in relapsed/refractory setting) after a median follow up of 88.8 months. For the first line setting, median PFS and OS were remarkably good, with a CR rate of 48.3%, median PFS of 30.2 months and 10-year OS of 51%. We found no difference in outcome for patients with high-risk metaphase cytogenetics or FISH del(13q14), but efficacy in current standard high-risk patients could not be determined. The outcome in the relapsed/refractory setting was poor, especially in the subgroup of patients relapsing within 18 months after auto-SCT. Therefore, if applied at all in these patients, improvement of allo-SCT is needed, focusing on reduction of TRM and more effective immunotherapy. This article is protected by copyright. All rights reserved.

 European Journal of Haematology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.